

MATERIAL SAFETY DATA SHEET

Issue Date: March 2001

Revision No.: 7

Revision Date: April 2016

SECTION 1 – Identification of the Material and Supplier

Product Name PENTHROX® (METHOXYFLURANE)

Product Code(s) ME-MEOTH, ME-7590-45, ME-MS245, ME-MS246, ME-

MS260

Recommended Use Inhalation analgesic - for pre-hospital pain relief and short

surgical procedures

Other Names 2,2-dichloro-1,1-difluoromethoxyethane; 2,2-dichloro-1,1-

difluoroethylmethyl ether; Ethane, 2,2-dichloro-1,1-difluoro-1-

methoxy; Ether, 2,2-dichloro-1,1-difluoroethyl methyl

Company Name Medical Developments International Ltd. (ABN 14 106 340

667)

Address 4 Caribbean Drive, Scoresby, Victoria, Australia, 3179

Fax +61 (3) 9547 0262 **Phone** +61 (3) 9547 1888

Emergency Contact 13 11 26 (Poisons Information Centre - 24 hours)

Infosafe No. ACOFS

PENTHROX INHALER

Methoxyflurane must only be administered using the Penthrox Inhaler, a polyethylene tube incorporating a polypropylene wick. Do not exceed recommended dose. The Penthrox Inhaler is a single-patient use device. After use, place used Penthrox Inhaler and bottle in sealed plastic bag and dispose of responsibly through normal waste.

SECTION 2 – Hazards Identification

Hazard Classification HAZARDOUS SUBSTANCE, NON DANGEROUS GOODS

(Classified as Hazardous according to the criteria of NOHSC)

Risk Phrase(s) R36/37/38 - Irritating to eyes, respiratory system and skin.

R67 - Vapours may cause drowsiness and dizziness.

Safety Statement(s) S24/25 - Avoid contact with eyes and skin.

S46 - If swallowed, seek medical advice immediately and show

this container or label.

S51 - Use only in well-ventilated areas.

SECTION 3 – Composition/Information on Ingredients

Compound/Ingredient	CAS Number	Proportion
Methoxyflurane	76-38-0	>99.9%
Butylated hydroxytoluene (BHT)	128-37-0	0.01%

SECTION 4 – First Aid Measures

Swallowed DO NOT INDUCE VOMITING. Rinse mouth with water and

then give water to drink. Seek immediate medical

assistance.

Eye Immediately irrigate with copious amounts of water for at

least 15 minutes. Eyelids to be held open. In all cases of eye contamination it is a sensible precaution to seek medical

attention.

Skin Wash contaminated skin with plenty of soap and water.

Remove contaminated clothing and wash before re-use. If

irritation occurs seek medical attention.

Inhaled Fresh air, rest. Refer for medical attention.

First Aid Facilities Eye wash and normal washroom facilities.

Advice to Doctor Treat symptomatically.

SECTION 5 – Fire Fighting Measures

Suitable Extinguishing Media CO₂, Powder, Water spray, Foam.

Hazards from Combustion Carbon Monoxide, Carbon Dioxide, Hydrogen Chloride,

Hydrogen Fluoride.

Precautions for fire fighters

& special protective

Equipment

Wear full protective suit.

Wear self-contained breathing apparatus

MSDS – Methoxyflurane Page 3 of 8

SECTION 6 – Accidental Release Measures

Emergency Procedures Alert all nearby personnel of potential Hazard and evacuate

area

Ensure adequate ventilation before entering affected area

Wear protective equipment and clothing

Keep unprotected persons away from affected area

Remove/Isolate all ignition sources.

Environmental Precautions Do not allow the material to be released to the environment

without proper governmental permits

Methods and Materials for Absorb with liquid-binding material (sand, diatomite,

sawdust, vermiculite).

Contamination and Clean up

procedures

Wear self-contained breathing apparatus. Wear protective equipment and clothing. Dispose of all contaminated material

according to local waste legislations.

SECTION 7 – Handling and Storage

Precautions for safe handling Avoid contact with skin and eyes. Avoid inhalation of vapour

or mist.

See section 2 for precautions.

Storage Conditions Store in a tightly closed container. Avoid direct contact with air

or light. Keep separated from incompatible substances. Store in a well-ventilated area away from foodstuff. Keep bulk

containers closed at all times - check regularly for leaks. This material is a Prescription Only Medicine. Store in

accordance with local regulations & standards.

SECTION 8 – Exposure Controls/Personal Protection

National exposure Standards There is currently no established exposure standard for

Methoxyflurane. There are, however, well established standards for Halothane, which is regarded as the most studied of the halogenated inhalational anaesthetic agents. Halothane standards are generally accepted as applicable to all agents in this class, including Methoxyflurane. The threshold limit value (TLV) for Halothane is set at 50 ppm for use as a single agent as stated by the American ACGIH.

Other Exposure Information An Occupational exposure limit has not been established for

methoxyflurane by NIOSH. Human clinical and toxicity data have been independently reviewed and used to derive a

Medical Developments International Limited ABN 14 106 340 667 4 Caribbean Drive, Scoresby, Victoria, AUSTRALIA 3179

MSDS - Methoxyflurane Page 4 of 8

Maximum Exposure Limit (MEL) of 15 ppm.

Engineering Controls DO NOT enter confined spaces where vapour may have

> collected. Use in well ventilated areas. Where ventilation is inadequate, local exhaust ventilation should be used. Vapour is heavier than air - prevent concentration in hollows or sumps.

Keep containers closed when not in use.

Personal Protective Equipment FOR BULK HANDLING or SPILL CLEANUP:

> RESPIRATOR TYPE: Where ventilation is inadequate, the use of an Air Purifying Respirator with a Type A Organic Vapour filter complying with AS/NZS 1715 and AS/NZS 1716 is

recommended.

EYE PROTECTION: Safety glasses or goggles.

GLOVE TYPE: PVA gloves.

CLOTHING: Overalls or similar protective clothing.

SECTION 9 – Physical and Chemical Properties

Appearance Clear, colourless liquid Odour Characteristic odour pН Not applicable **Vapour Pressure** 2.66 kPa @ 17.7℃ **Vapour Density (absolute)** 7.36 g/L @ 37 °C

Boiling Point 104.6℃ **Melting Point** -35℃

Solubility in Water <1 mg/L @ 19℃

Specific Gravity 1.426 g/ml @ 25 °C (water = 1) **Flash Point** 63 °C (Open Cup method) 38 °C (Closed Cup method)

Combustibility Rate Does not sustain combustibility @75 °C for 30 sec.

Flamm. Limit LEL

Flamm. Limit UEL Not available **Decomposition Temp.** Not Determined

99.9% **Volatile Component**

Solubility in Organic Soluble in acetone, alcohol, chloroform, ether, acetonitrile, oils.

Stable under normal conditions, may be sensitive to prolonged

exposure to light.

Haz. Polymerization Will not occur.

Materials to Avoid Oxidising agents and powdered metals.

Formula C₃HOCl₂F₂ **Molecular Weight** 164.97

SECTION 10 – Stability and Reactivity

Chemical Stability Stable at normal temperatures and pressures.

Stability

MSDS – Methoxyflurane Page 5 of 8

Conditions to avoid Avoid heat, flames, sparks and other sources of ignition.

Sealed containers may rupture or explode if exposed to high levels of heat. Keep out of water supplies and sewers.

Incompatible materials Oxidizing materials. Finely powdered metals.

Hazardous decomposition

products

Thermal decomposition products: Halogenated compounds,

oxides of carbon

Hazardous reactions Will not polymerize.

SECTION 11 – Toxicological Information

Acute - Swallowed The liquid may be discomforting to the gastrointestinal tract and

may cause nausea and vomiting.

Acute - EyeThe liquid is irritating to the eyes and may cause pain and redness.

Acute - Skin Prolonged or repeated skin contact with the liquid may cause

irritation.

Acute - Inhaled The vapour may be irritating to the upper respiratory tract.

Exposure to low vapour concentrations can cause headache and nausea. (High vapour concentrations, such as when used as an anaesthetic, have a depressant action on the central nervous

system producing loss of consciousness.)

Chronic Chronic inhalation of methoxyflurane in high doses may cause liver

and kidney damage. It has been reported that volatile agents may increase the risk of spontaneous abortion. To our knowledge there

have been no reported cases of this occurring when

methoxyflurane is used as an analgesic. However, during early pregnancy, exposure to any volatile agent should be limited or

avoided, as with many medications as a precaution.

The presence of other drugs or pre-existing medical conditions may increase the effects of methoxyflurane on the renal system, but only

when used in anaesthetic quantities.

Toxicology Oral (rat): LD50: 3600 mg/kg

Inhalation (rat): LC50: 33,500 mg/m³/4H Inhalation (human): TCLo: 3,500 ppm/1H Eye (rabbit): 100 mg (moderate irritation)

SECTION 12 – Ecological Information

Ecotoxicity No data available. Do not allow to access drains or sewers.

Persistence & Degradability No data available.

Mobility No data available.

SECTION 13 – Disposal Considerations

Dispose of product in accordance with all applicable local and federal regulations. May be subjected to specific disposal regulations.

SECTION 14 – Transport Information

UN Number IATA-DGR: Non dangerous goods

IMDG: Non dangerous goods ADR/RID: Non dangerous goods

UN proper shipping name IATA-DGR: Non dangerous goods

IMDG: Non dangerous goods ADR/RID: Non dangerous goods

Class and Subsidiary Risk IATA-DGR: Non dangerous goods

IMDG: Non dangerous goods ADR/RID: Non dangerous goods

Packaging Group IATA-DGR: Non dangerous goods

IMDG: Non dangerous goods ADR/RID: Non dangerous goods

Special Precautions for

user

This material is a Prescription Only Medicine and must be stored, maintained and used in accordance with both local & federal

va sulations

regulations.

Hazchem Code 3Z

Other Information Methoxyflurane is not a dangerous goods or mixture according to

Australian Dangerous Goods Code (Edition 7.3, August 2014 – section 2.3.1.1) and the IATA Dangerous Goods Regulations (54th Edition, January 2013 – section 3.3.1.3). Liquid meeting the definition of these codes with a flash point of more than 35C which to not sustain combustion need not be considered as flammable

liquids for the purpose of this code.

SECTION 15 – Regulatory Information

Regulatory Status of methoxyflurane under relevant Australian health, safety and environmental legislation:

- (a) SUSMP methoxyflurane is Schedule 4 (Prescription Only Medicine)
- (b) Any applicable prohibition or notification/licensing requirements including for carcinogens under commonwealth, state or territory legislation none
- (c) Agricultural and Veterinary Chemicals Act 1988 none
- (d) AICS listed

This product is classified as Hazardous according to the criteria of NOHSC.

Additional information:

CERCLA/SARA Hazardous Substances: Not applicable.

CERCLA (Superfund) reportable quantity: None

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard Yes

Delayed Hazard Yes

Fire Hazard Yes

Pressure Hazard No

Reactivity Hazard No

Section 302 extremely hazardous substance No

Section 311 hazardous chemical No

Inventory status

Country(s) or region	Inventory name On inventory	On inventory (yes/no)*	
Australia	Australian Inventory of Chemical Substances (AICS)	Yes	
Canada	Domestic Substances List (DSL)	No	
Canada	Non-Domestic Substances List (NDSL)	No	
China	Inventory of Existing Chemical Substances in China (IECSC)	No	
Europe	European Inventory of Existing Commercial Chemical Substan	ces Yes	

(EINECS)

Europe	European List of Notified Chemical Substances (ELINCS)	No Yes
Japan Korea	Inventory of Existing and New Chemical Substances (ENCS) Existing Chemicals List (ECL)	No.
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

SECTION 16 – Other Information

Contact Poisons information Centre (24 hours) Tel: 13 11 26

Infosafe No. ACOFS

IMPORTANT NOTE:

Copyright 2014 Medical Developments International Ltd. The information contained in this Material Safety Data Sheet is, to the best of our knowledge, true and accurate, but any recommendations or suggestions that may be made are without guarantee since the conditions of use are beyond our control. Medical Developments International Ltd. does not assume any legal responsibility for use or reliance upon this information. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

...End of MSDS...